Yatharth Hospital & Trauma Care Services Ltd

Yatharth Hospital & Trauma Care Services Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Feb 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Yatharth Hospital & Trauma Care Services Ltd has experienced a notable shift in its valuation parameters, moving from fair to expensive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, signals a diminished price attractiveness relative to its historical averages and peer group. Investors should carefully analyse these valuation dynamics amid the company’s recent market performance and sector context.

Yatharth Hospital & Trauma Care Services Ltd has recently undergone a notable change in its valuation parameters, shifting from an expensive to a fair valuation grade. This adjustment, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, marks a significant development for investors assessing the hospital sector’s evolving landscape. Despite a recent downgrade in its overall Mojo Grade to Sell, the stock’s valuation now appears more attractive relative to its historical averages and peer group, warranting a closer examination of its price dynamics and market positioning.

Yatharth Hospital & Trauma Care Services Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 February 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 03 March 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.

Yatharth Hospital & Trauma Care Services Ltd witnessed a sharp decline at market open on 2 Mar 2026, opening with a gap down of 8.1% amid broader sector underperformance and a downgrade in its Mojo Grade. The stock’s weak start reflects heightened market concerns despite a positive one-month performance relative to the Sensex.

Yatharth Hospital & Trauma Care Services Ltd is rated 'Sell' by MarketsMOJO. This rating was last updated on 06 February 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 20 February 2026, providing investors with the latest perspective on the company’s position.

Yatharth Hospital & Trauma Care Services Ltd has seen a notable shift in its valuation parameters, moving from fair to expensive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, raises questions about the stock’s price attractiveness relative to its historical averages and peer group within the hospital sector.

Yatharth Hospital & Trauma Care Services Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a complex interplay of valuation adjustments, technical indicators, financial trends, and quality assessments. Despite strong financial performance and market-beating returns over the past year, recent technical signals and promoter stake reductions have weighed on investor sentiment, prompting a reassessment of the stock’s outlook.

Yatharth Hospital & Trauma Care Services Ltd has experienced a subtle but notable shift in its technical parameters, moving from a mildly bullish to a mildly bearish trend. This change is underscored by a combination of momentum indicators and moving averages that suggest caution for investors amid mixed signals from key technical tools.

Yatharth Hospital & Trauma Care Services Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, reflecting deteriorating momentum and raising concerns about the stock’s medium to long-term outlook.

Yatharth Hospital & Trauma Care Services Ltd. reported robust growth in Q3 FY26, with consolidated net profit surging 48.74% year-on-year to ₹45.35 crores, marking the company's strongest quarterly performance to date. The small-cap hospital chain, with a market capitalisation of ₹6,013 crores, demonstrated impressive operational scale-up with revenues jumping 46.23% YoY to ₹320.47 crores, though margin compression remained a concern as operating margins contracted sequentially.

Yatharth Hospital & Trauma Care Services Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an expensive rating. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, signals a recalibration of the stock’s price attractiveness relative to its historical averages and peer group. Investors and analysts are now reassessing the hospital sector player’s market positioning amid evolving financial fundamentals and sector dynamics.

Yatharth Hospital & Trauma Care Services Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in technical indicators and steady financial performance. The upgrade, effective from 1 February 2026, is driven by a combination of enhanced technical trends, solid quarterly results, and a balanced valuation outlook amid evolving market dynamics.

Yatharth Hospital & Trauma Care Services Ltd has exhibited a notable shift in its technical momentum, moving from a mildly bearish stance to a mildly bullish trend. This change is underscored by a blend of mixed signals from key technical indicators such as MACD, RSI, Bollinger Bands, and moving averages, reflecting a nuanced outlook for investors in the hospital sector.

Yatharth Hospital & Trauma Care Services Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a transition from sideways movement to a mildly bearish trend. Despite some bullish cues on shorter-term oscillators, the overall technical landscape suggests caution for investors as the stock price declined by 3.04% on 27 Jan 2026, reflecting growing selling pressure amid broader market challenges.